Geron Corp Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Geron Corp filed its Q1 2024 10-Q, detailing financial instruments and corporate information.</b>

AI Summary

GERON CORP (GERN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Geron Corp filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to fair value measurements for recurring items as of March 31, 2024, and December 31, 2023. Specific financial instruments mentioned include U.S. Treasury Securities, Commercial Paper, Certificates of Deposit, and Money Market Funds. The company's fiscal year ends on December 31. Geron Corp is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking GERON CORP, this filing contains several important signals. This filing provides a snapshot of Geron Corp's financial position and investment holdings as of the end of the first quarter of 2024. Understanding the specific financial instruments and their valuation methods is crucial for assessing the company's liquidity and investment strategy.

Risk Assessment

Risk Level: low — GERON CORP shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain significant new information or indicate immediate financial distress.

Analyst Insight

Review the detailed fair value measurements and investment holdings to understand the company's asset allocation and potential risks.

Key Numbers

• 2024-03-31 — Period of Report (Conformed period of report)
• 2024-05-02 — Filed As Of Date (Filed as of date)
• 1231 — Fiscal Year End (Fiscal year end)
• 2834 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• GERON CORP (company) — Filer name
• 2024-03-31 (date) — Period of report
• 2024-05-02 (date) — Filed as of date
• DE (jurisdiction) — State of incorporation
• 1231 (date) — Fiscal year end
• PHARMACEUTICAL PREPARATIONS (industry) — Standard Industrial Classification
• 6504737700 (phone) — Business phone
• FOSTER CITY (location) — Business address city

FAQ

Industry Context

Geron Corp operates in the Pharmaceutical Preparations industry (SIC 2834).

Regulatory Implications

The filing is a standard 10-Q report under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the fair value measurements of financial instruments as of March 31, 2024.
2. Review the company's fiscal year end and incorporation details.
3. Note the SIC code for industry classification.

Year-Over-Year Comparison

This is the Q1 2024 10-Q filing, providing updated financial information compared to previous filings.

Key Financial Figures

• $0.001 — ge on which registered: Common Stock, $0.001 par value GERN The Nasdaq Stock Mar

Filing Documents

• gern-20240331.htm (10-Q) — 1845KB
• gern-ex31_1.htm (EX-31.1) — 15KB
• gern-ex31_2.htm (EX-31.2) — 15KB
• gern-ex32_1.htm (EX-32.1) — 8KB
• gern-ex32_2.htm (EX-32.2) — 8KB
• 0000950170-24-052074.txt (&nbsp;) — 7337KB
• gern-20240331.xsd (EX-101.SCH) — 1012KB
• gern-20240331_htm.xml (XML) — 1379KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1:

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2:

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3:

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4:

Controls and Procedures

Controls and Procedures 30

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1:

Legal Proceedings

Legal Proceedings 30 Item 1A:

Risk Factors

Risk Factors 31 Item 2: Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 67 Item 3: Defaults Upon Senior Securities 67 Item 4: Mine Safety Disclosures 67 Item 5: Other Information 67 Item 6: Exhibits 68

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) GERON CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS) MARCH 31, DECEMBER 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 189,761 $ 70,023 Restricted cash 1,119 1,115 Marketable securities 253,288 263,676 Interest and other receivables 1,629 1,655 Prepaid and other current assets 5,712 4,879 Total current assets 451,509 341,348 Noncurrent marketable securities 20,782 43,298 Property and equipment, net 1,681 1,177 Operating leases, right-of-use assets 3,392 3,556 Deposits and other assets 4,710 4,697 $ 482,074 $ 394,076 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 9,992 $ 6,161 Accrued compensation and benefits 6,794 13,759 Operating lease liabilities 955 949 Debt 71,526 46,893 Accrued liabilities 33,891 40,308 Total current liabilities 123,158 108,070 Noncurrent operating lease liabilities 2,829 3,006 Noncurrent debt 11,219 35,051 Commitments and contingencies Stockholders' equity: Common stock 591 545 Additional paid-in capital 1,997,709 1,844,988 Accumulated deficit ( 1,653,159 ) ( 1,597,769 ) Accumulated other comprehensive loss ( 273 ) 185 Total stockholders' equity 344,868 247,949 $ 482,074 $ 394,076 See accompanying notes. 3 GERON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) (UNAUDITED) THREE MONTHS ENDED MARCH 31, 2024 2023 Revenues: Royalties $ 304 $ 21 Operating expenses: Research and development 29,373 27,219 General and administrative 27,065 12,894 Total operating expenses 56,438 40,113 Loss from operations ( 56,134 ) ( 40,092 ) Interest income 4,239 3,853 Interest expense ( 3,433 ) ( 1,922 ) Other income and (expense),

View Full Filing

View this 10-Q filing on SEC EDGAR